"The U.S. Food and Drug Administration today approved Sovaldi (sofosbuvir) to treat chronic hepatitis C virus (HCV) infection. Sovaldi is the first drug that has demonstrated safety and efficacy to treat certain types of HCV infection without the "...
Roferon-A (interferon alfa-2a, recombinant) is contraindicated in patients with:
- Hypersensitivity to Roferon-A (interferon alfa-2a, recombinant) or any of its components
- Autoimmune hepatitis
- Hepatic decompensation (Child-Pugh class B and C) before or during treatment
Roferon-A (interferon alfa-2a, recombinant) is contraindicated in neonates and infants because it contains benzyl alcohol. Benzyl alcohol is associated with an increased incidence of neurologic and other complications in neonates and infants, which are sometimes fatal.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 11/11/2008
Additional Roferon-A Information
Roferon-A - User Reviews
Roferon-A User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.